Understand the source comparison
ARA-290 Small Fiber Neuropathy: Treatment Comparison
Different approaches to small fiber neuropathy address distinct aspects of the condition. Some target pain transmission, others modify underlying disease processes, and a few like ARA-290 aim for nerve regeneration. Understanding these mechanisms clarifies why
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different approaches to small fiber neuropathy address distinct aspects of the condition. Some target pain transmission, others modify underlying disease processes, and a few like ARA-290 aim for nerve regeneration. Understanding these mechanisms clarifies why combination approaches often outperform monotherapy.
- ARA-290 (Tissue-Protective Peptide)
- Activates innate repair receptor (EpoR/CD131 complex) to promote axonal survival and regeneration through JAK2-STAT3 and PI3K-Akt signaling
- Yes. Clinical trials show increased IENFD by skin biopsy and corneal nerve fiber density improvements
- 4–8 weeks for pain reduction; 8–12 weeks for nerve fiber density changes
- Addresses underlying pathology rather than symptoms alone; most effective in inflammatory subtypes
- Gabapentinoids (Gabapentin, Pregabalin)
- Bind α2δ subunit of voltage-gated calcium channels, reducing neurotransmitter release in pain pathways
- No. Purely symptomatic; no effect on nerve fiber counts
- 1–3 weeks for pain modulation
- First-line for neuropathic pain management but does nothing to slow nerve loss progression
- Topical Capsaicin 8% Patch
- Depletes substance P from C-fiber terminals, causing temporary desensitization of nociceptors
- No. Causes temporary functional denervation but not structural repair
- 2–4 weeks post-application
- Useful for localized pain but requires clinical application and causes initial severe burning
- Alpha-Lipoic Acid (600 mg daily)
- Antioxidant that reduces oxidative stress and may improve endothelial function in vasa nervorum
- Possible. German trials show modest IENFD improvement in diabetic neuropathy
- 12–24 weeks
- Best evidence in metabolic neuropathy; effect size smaller than ARA-290 but excellent safety profile
- Immunoglobulin Therapy (IVIG)
- Provides passive immunomodulation, reducing autoantibody-mediated nerve damage in immune-mediated cases
- Indirect. Reduces ongoing damage rather than promoting regeneration
- 6–12 weeks
- Reserved for confirmed autoimmune etiologies; very expensive and requires infusion clinic access
- Clinical practice increasingly recognizes that small fiber neuropathy management requires addressing both symptom control and disease modification. Gabapentinoids provide rapid pain relief while ARA-290 works toward structural repair. The mechanisms are complementary rather than redundant. Patients with severe baseline pain often require initial gabapentinoid therapy to achieve tolerable symptom levels before meaningful nerve regeneration can occur over subsequent months.
- The evidence hierarchy for nerve regeneration currently places ARA-290 above oral supplements but below definitive disease-modifying treatments for specific etiologies (such as gluten-free diet for celiac neuropathy or immunosuppression for vasculitic neuropathy). If a reversible underlying cause exists, addressing that cause remains the priority. ARA-290 becomes most relevant when the underlying disease is controlled but residual nerve damage persists, or when the etiology is idiopathic despite exhaustive investigation.